Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

"Who's on First?"

"Who's on First?" EDITORIAL Considering the Options for Primary Glaucoma Therapy IFTY YEARS AGO, it was unlikely that any- scription medication regimen. Furthermore, occa- one would have dreamed that Abbott and sional ocular side effects such as conjunctival hyper- Costello’s “Who’s on First?” routine would emia, can subsequently influence the outcome of filtration survive the turn of the century. By using ge- surgery. Less commonly, hypertrichosis, iris pigmenta- F neric pronouns such as “who,” “what,” and tion, and darkening of the periocular skin may further other commonly used phrases such as, “I don’t know,” discourage a glaucoma patient to adhere to his or her this comedic routine became a template for debates other regimen. than those pertaining to a fictional baseball team. The So what about laser therapy? Following the comple- players are generic enough that the story can easily ap- tion of the Glaucoma Laser Trial, one may have antici- ply to other settings; the thematic overtones are also uni- pated that primary laser therapy would become a versal. For example, a seemingly simple question be- preferred practice pattern for glaucoma practice. In ad- comes more complex when one considers more dition, the Advanced Glaucoma Intervention Study noted dimensions of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

"Who's on First?"

Higginbotham, Eve J.
JAMA Ophthalmology , Volume 120 (2) – Feb 1, 2002
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/who-s-on-first-XUYuKGDLXR

References (19)

Publisher
American Medical Association
Copyright
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.120.2.191
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Considering the Options for Primary Glaucoma Therapy IFTY YEARS AGO, it was unlikely that any- scription medication regimen. Furthermore, occa- one would have dreamed that Abbott and sional ocular side effects such as conjunctival hyper- Costello’s “Who’s on First?” routine would emia, can subsequently influence the outcome of filtration survive the turn of the century. By using ge- surgery. Less commonly, hypertrichosis, iris pigmenta- F neric pronouns such as “who,” “what,” and tion, and darkening of the periocular skin may further other commonly used phrases such as, “I don’t know,” discourage a glaucoma patient to adhere to his or her this comedic routine became a template for debates other regimen. than those pertaining to a fictional baseball team. The So what about laser therapy? Following the comple- players are generic enough that the story can easily ap- tion of the Glaucoma Laser Trial, one may have antici- ply to other settings; the thematic overtones are also uni- pated that primary laser therapy would become a versal. For example, a seemingly simple question be- preferred practice pattern for glaucoma practice. In ad- comes more complex when one considers more dition, the Advanced Glaucoma Intervention Study noted dimensions of the

Journal

JAMA Ophthalmology – American Medical Association

Published: Feb 1, 2002

There are no references for this article.